Infant GERD Studies For PPIs Need Narrower Populations, Advisory Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Gastrointestinal Drugs Advisory Committee reaches broad agreement that the pathophysiology of GERD is not the same in infants as it is in adults, although a few are vocal that it is in fact the same.
You may also be interested in...
PPIs For Infants: FDA Summons Advisory Panel, But Industry Unenthusiastic
In this instance, FDA seems more interested than the sponsors in a potential market expansion.
PPI Efficacy Studies In Certain Infants May Be Needed, Cmte. Says
Proton pump inhibitor efficacy studies in certain infants under one year of age may be needed, members of FDA's Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee generally agreed at its June 11 meeting
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.